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Endoscopy is a valuable clinical tool for the clinician who takes care of patients with inﬂammatory bowel disease (IBD). The role
of endoscopy in the diagnosis, management, and treatment of IBD is discussed in this review. The central role that colonoscopy
plays in screening for colon cancer in patients with longstanding IBD is also addressed.
1.Introduction
Endoscopy is an essential clinical tool to assist in the
diagnosis and management of inﬂammatory bowel disease
(IBD)[1].Bydirectvisualinspectionoftheintestinalmucosa
usedinconjunctionwithhistologyfrombiopsies,adiagnosis
of IBD can be made. Proper use of endoscopy with biopsies
also enables evaluation of other disorders that may mimic
the gastrointestinal features of IBD. Once the diagnosis of
IBD is made, endoscopy is performed to assess the severity
and location of inﬂammation, and to evaluate for other
disease possibilities in the midst of a ﬂare. Response to
medical treatment or surveillance for postoperative disease
recurrence may also be evaluated. Finally, endoscopy is used
in colon cancer surveillance in those with longstanding IBD.
The role of endoscopy in these areas will be reviewed in this
paper. The emerging role of wireless capsule endoscopy and
endoscopic ultrasound in IBD will not be addressed.
2.Endoscopy inthe Diagnosisof IBD
Because IBD is a chronic lifelong condition that requires
careful medical management and followup and can be
associated with signiﬁcant morbidity with hospitalizations
and surgeries, establishing that the diagnosis is essential.
Once IBD is suspected based on clinical signs and symp-
toms, laboratory, and/or radiology studies, endoscopy with
mucosal biopsies adds considerably to the diagnosis [2, 3].
The index colonoscopy is critical in establishing the disease
extentandseverity.Specialnotemustbemadeoftheperianal
area for tags, ﬁssures, strictures, and ﬁstula tract openings
which may suggest Crohn’s disease (CD). The rectal mucosa
must be carefully inspected and biopsied to evaluate for at
leastmicroscopicinﬂammationasinvolvementhereisalways
present in ulcerative colitis (UC) [4].
Close attention to the mucosal features seen throughout
the colon can help suggest IBD and even decipher between
UC and CD. Sensitive endoscopic features to establish a
diagnosis of CD are patchiness of the disease extent, apthous
ulcers (Figure 1(a)), and cobblestoning [3]( Figure 1(b)). It
is the penetrating nature into the deeper layers of the colon
wall that can sometimes give the characteristic cobblestoning
appearance. The discrete ulcerations associated with CD
are also suggestive of this diagnosis and include linear or
serpiginous ulcers (Figure 1(c)). Other features of CD that
can be assessed at index colonoscopy include evidence of
strictures in the colon, ileocecal valve, or terminal ileum
(Figure 1(d)). A colonic stricture in a suspected patient with
UC should raise concern for malignancy. Likewise, strictures
that are not able to be passed with the endoscope need
further evaluation, usually with radiographic imaging. The
vascular pattern in CD is also important to note and can
represent the patchy nature of CD: normal vasculature might
be found next to abnormally inﬂamed mucosa where the
vessels are apparently absent. In UC, it is essential to evaluate
and document the extent of inﬂammation seen which will
ultimatelyhelpclassifythepatientashavingproctitis(disease
limited to the rectum), left-sided disease (disease extends2 Diagnostic and Therapeutic Endoscopy
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Figure 1: Endoscopic features of Crohn’s disease. Several key endoscopic features of Crohn’s disease are depicted including apthous ulcers
(a), cobblestoning (b), serpiginous ulcers (c), and a stricture in the terminal ileum (d).
to the splenic ﬂexure), or pancolitis (the entire colon is
involved). The severity of inﬂammation in UC is the other
piece of information that is important to note. A mild degree
of inﬂammation as assessed by endoscopy is associated
with a loss of the appearance of blood vessels, erythema,
and a granular appearance to the mucosa (Figure 2(b)).
Moderate disease is associated with mildly erosive disease
with increased erythema and edema (Figure 2(c)). Colons
with severe disease have ulcers, exudates, and spontaneous
bleeding(Figure 2(d)).Itmaybehelpfultouseanestablished
grading system in the assessment of the involved mucosa
which can then be used to compare future procedures and
provide information to the pathologist in a standard manner
[5].
Ileoscopy is imperative in the initial colonoscopy when
evaluating for IBD [6]. Careful inspection of the ileocecal
valve for erosions, ulcers, and strictures should be noted
prior to intubation of the ileum. In a suspected UC patient
without pancolitis, the terminal ileum should be entirely
normal. However, if the disease extends through to the
cecum, then the appearance of the so called “backwash”
ileitis may be noted as erythema and even erosive disease.
Ileal involvement in UC was studied in 200 consecutively
collected colon resection specimens. In this study, 17% were
found to have evidence of ileal involvement [7]. Although
the vast majority of these patients had pancolitis (94%), the
others did not have cecal involvement. The clinical message
from this study is that ileal involvement in a UC patient
does not always mean that the diagnosis should be switched
to CD. Biopsies of the ileum should always be performed
and interpreted using the full clinical context even if the
endoscopic appearance is normal [8]. In suspected CD, the
terminal ileum should be evaluated for erythema, erosions,
ulcers (Figure 3(a)), and strictures. It is important to keep
in mind and to note whether or not a patient has been
taking NSAIDmedications whentheterminalileumﬁndings
are ultimately documented and interpreted. Prior usage of
NSAIDs can lead to identical endoscopic ﬁndings as those
seen in CD (Figure 3(b)).
There are several other points to consider regarding
the index colonoscopy. One must always assess the relative
safety of a full colonoscopy and ileoscopy in those that have
moderate-to-severe inﬂammation, signiﬁcant pain prior to
the procedure, or other medical relative contraindications
to the procedure. In these instances a more limited ﬂexible
sigmoidoscopy may still allow for some mucosal visualiza-
tion and allow for biopsies in suspected UC and colonic
CD. Radiologic studies may be helpful in right-sided colonic
CD or ileal disease. Once a patient has been started on
treatment and the severity of disease is presumed to be less
and the patient is without pain, then a full colonoscopy with
ileoscopy can be performed safely. It is important to keep
in mind, however, that medical treatment can potentially
change the natural endoscopic appearance of the patient’s
colon [9]. Topical therapy in the form of suppositories or
enemas can yield relative sparing of the rectum and/or left
colon, respectively. Systemic medications have also been
known to cause a “patchy” distribution of endoscopic
inﬂammation that may be misinterpreted as a classic feature
for CD. Biopsies of involved and uninvolved areas of colon
and performing the colonoscopy prior to the institution of
medical therapy will help avoid these potential pitfalls inDiagnostic and Therapeutic Endoscopy 3
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Figure 2: Endoscopic features of ulcerative colitis images of the various degrees of severity of inﬂammation as assessed by endoscopy are
shown compared to a normal colon (a). Mild inﬂammation is depicted in (b), moderate inﬂammation in (c), and severe inﬂammation in
(d).
(a) (b)
Figure 3: Findings in the terminal ileum. An ulcer (black arrow) is seen 3cm proximal to the ileocecal valve in a patient with Crohn’s disease
(a). Erosions in the terminal ileum are shown in a patient who presented with guaiac positive stools and had been taking NSAIDs for back
pain (b).
diagnosis. Disease that is de novo also might not possess
the classic endoscopic features of IBD. Newly diagnosed UC
may be patchy for instance and have relative or absolute
rectal sparing [10]. Similarly, severe UC may possess many of
the endoscopic features we associate with CD such as deep,
ﬁssuring ulcers, patchy distribution, and ileal involvement
[11]. Lastly, UC patients even in the absence of pancolitis
may have involvement of the periappendiceal area—the so-
called cecal patch [12]. Although this has been found to have
no clinical or prognostic signiﬁcance in these patients, it
should be noted and not confused with a diagnosis of CD.
There are several other conditions that may mimic the
clinical signs and symptoms of IBD and a colonoscopy
should always be considered for the diagnosis [13]. The
endoscopic features of these entities alone may overlap and
be nonspeciﬁc, and so biopsies and the clinical scenario are
necessary to factor in. Infectious colitis is the most common
entity that can present like IBD and cause features such as
abdominal pain, bloody diarrhea, and terminal ileal disease.
In one older prospective study of patients presenting with
acute hemorrhagic colitis-type symptoms, infectious colitis
was found to be the cause in 38% of the cases [14]. It is
importanttoobtainstoolculturesandc.diﬃcilestudiesprior
to, or at, the time of colonoscopy to aid in the diagnosis
of infectious colitis. Tuberculosis is a consideration when a
narrowed,nodularileumand/orcharacteristicdestructionof
the ileocecal valve [15] is encountered, and the appropriate
studies should be obtained if tuberculosis is suspected.
In infectious colitis, biopsies will not show the histologic
features of chronicity such as architectural distortion, basal4 Diagnostic and Therapeutic Endoscopy
plasmacytosis, Paneth cell hyperplasia, or pyloric gland
metaplasia [16]. Ischemic colitis may have a patchy distri-
bution with varying endoscopic involvement but usually is
localized to characteristic locations at the splenic ﬂexure or
right colon and is found in an at-risk patient. Biopsies in
involved and uninvolved areas will conﬁrm this diagnosis.
Similarly, the colitis associated with diverticulosis will be
patchy and conﬁned to an area populated by diverticula. The
presence of diverticula should be relayed to the pathologist
to help with their interpretation. Radiation colitis can be
seen in an at-risk patient, and certain medications especially
NSAIDs can yield any of the characteristic lesions seen
on endoscopy in IBD [17]. The use of these potentially
oﬀending medications should always be noted. Finally,
microscopic colitis despite its name may be associated with
mild endoscopic changes such as erythema and edema, and
its diagnosis should be interpreted carefully in conjunction
with the biopsy results and clinical presentation.
T h e r em a yb ear o l ef o ru p p e re n d o s c o p yi nt h e
patient initially suspected of having IBD, particularly in
the young patient with upper intestinal symptoms. Up to
13% of patients with CD may have involvement of the
gastrointestinal tract proximal to the ligament of Treitz [18],
with the esophagus, stomach, and duodenum all having
been reported. Endoscopic features may include erythema
and granularity, nodules, and bleeding. Histology may show
characteristic ﬁndings of chronic inﬂammation such as
architectural distortion combined with a chronic inﬂam-
matory inﬁltrate and granulomas [19]. Upper endoscopy
with biopsy might also be useful to rule out other causes
of symptoms such as celiac disease, peptic ulcer disease,
and eosinophilic diseases. Interestingly, the duodenum of
patients with UC has also been shown to be involved
endoscopically and does not necessarily support a diagnosis
of CD [19, 20].
Additional small bowel evaluations if indicated can
include capsule and double-balloon enteroscopy. These
modalities will not be discussed here and were recently re-
viewed elsewhere [21].
3. Endoscopy in the Management of
Established IBD
Once a diagnosis of IBD has been established, endoscopy is
an important tool to evaluate response to therapy, postoper-
ative recurrence, new worrisome symptoms, or contributing
factors in a ﬂare of the disease. Increasing evidence suggests
that mucosal healing is the optimal end point for medical
treatment both in UC and CD [22]. In UC, mucosal
healing leads to clinical remission and potentially lessens the
colon cancer risk overtime [23]. In CD, a prospective study
showed that mucosal healing results in clinical remission,
and reduced surgeries and hospitalizations at one year [24].
Endoscopy when combined with biopsies will make this
assessment,particularlywhentherecanbeapoorcorrelation
between the physician’s perception of how well a patient
is doing and the actual degree of endoscopic inﬂammation
[25]. Colonoscopy is indicated in IBD when there are
refractory or breakthrough symptoms to the established
medical treatment. In the patient with persistent pain and
loose stools for instance, endoscopy can determine whether
or not the symptoms are due to active inﬂammation. For the
same reason, it is important to perform a colonoscopy when
a new medical treatment is being considered. If there are any
new symptoms or signs such as worsening iron deﬁciency,
new bleeding weight loss, or fevers, endoscopy should also
be contemplated. If surgery is planned for either UC or CD,
a presurgery colonoscopy and ileoscopy is helpful for the
surgeon to help decide on the appropriate type and extent
of surgery.
Colonoscopy and ileoscopy is playing an increasing role
in the postoperative management of CD, particularly in
those who have undergone ileocecal resection. The endo-
scopic appearance 6–12 months after the surgery [26]c a n
help determine the risk of relapse of disease and decide
who should be on aggressive postoperative treatment [27].
Patients who have no disease or only a few scattered apthous
ulcers in the neoterminal ileum may likely be watched safely,
whereas patients with more severe endoscopic disease should
likely start medical therapy.
Endoscopy is also essential in the IBD patient who has
undergone ileal pouch anal anastomosis (IPAA). UC patients
areatriskforpouchitisthatcanleadtoabdominalpain,loose
stools, and rectal bleeding, and the characteristic features
can be noted on endoscopy (usually performed with an
upper endoscope). The pouch can appear erythematous,
ulcerated, exudative, and with varying degrees of bleeding.
Along with the direct endoscopic visualization, biopsies can
aid in making this diagnosis [28]. Careful inspection of the
aﬀerent limb may reveal a small degree of inﬂammation at
the distal most aspect suggestive of backwash and should
otherwise be normal, and this should be conﬁrmed with
biopsies. The diﬀerential diagnosis of pouchitis includes CD,
and this can be seen endoscopically with the characteristic
CD lesions in the pouch and involving the aﬀerent limb (not
just the distal most aspect). Cuﬃtis in those with a small
amount of retained rectal tissue is important to diagnose
with endoscopy and biopsy. As in other IBD patients,
one can evaluate for infections including c. diﬃcile. Lastly,
irritable pouch syndrome is a diagnosis that can be made in
the symptomatic patient whose pouch looks endoscopically
otherwise normal [29].
Endoscopy is an important clinical tool in the IBD
patient during a ﬂare of disease. As mentioned, endoscopy
will be able to determine fairly quickly if the new symptoms
are secondary to active inﬂammation. Endoscopy and biopsy
will also help to diﬀerentiate a true ﬂare of IBD versus
a complicating infection such as c. diﬃcile or CMV. It is
important to note that the appearance of c. diﬃcile in the
IBD patient may lack pseudomembranes and be diﬃcult to
distinguish from IBD alone without the aid of stool toxin
studies [30]. The key diagnostic ﬁnding in CMV is the
presence of viral inclusions in the mucosal tissue in an area
of active inﬂammation. Endoscopic features alone will not
allow one to make the diagnosis of CMV superimposed on
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4. EndoscopyforColorectalCancerSurveillance
No review of endoscopy in IBD would be complete without
discussing the important role that colonoscopy can play in
colorectal cancer surveillance. The American Gastroentero-
logical Association (AGA) has recently published a medical
position statement [31] and technical review [32] that
comprehensively detail the diagnosis and management of
colorectal neoplasia in IBD.
Although there has been no study to date that has
shown a direct mortality beneﬁt from colon cancer screening
in IBD with colonoscopy, it is accepted that cancers may
be detected earlier and at presumably curable stages. The
major gastrointestinal societies (AGA, American College
of Gastroenterology, American Society for Gastrointestinal
Endoscopy, British Society of Gastroenterology) have put
forth guidelines for the recommended starting times and
intervals for screening. Because the risk of colonic neoplasia
is probably similar in Crohn’s colitis as in UC [33], these
guidelines should also apply to patients with Crohn’s colitis
for similar extent, duration, and age of onset of disease. In
patients who have had pancolitis for eight years (starting
at the time of symptoms), screening should begin at 1-
2-year intervals. For left-sided disease, current guidelines
from most societies recommend starting screening after 15
years of disease. The exact interval of screening in this
latter group of patients is not established and the societies
recommend in general every 1-2 years. The British Society
of Gastroenterology suggests decreasing the yearly interval
of surveillance with each decade of disease (they suggest a
screening colonoscopy every 3 years in the second decade of
disease, every 2 years in the third decade, and every year in
the fourth decade [34]). Societies agree that patients with
isolated proctitis probably do not have to be screened for
colon cancer.
There are several factors that need to be taken into con-
sideration when determining the correct screening interval
for your patient. Patients who have had treatment refractory
or persistent inﬂammation throughout their IBD history
might be at increased risk for progression to neoplasia
[35], and one should consider starting surveillance sooner.
Whether or not a patient has a personal or family history of
adenomatous polyps or colon cancer should also be factored
in to the screening commencement time and interval. If
a patient has a concurrent diagnosis of primary sclerosing
cholangitis (PSC), it is recommended that colorectal cancer
screening start at the time of diagnosis of PSC and be
continued at yearly intervals. Patients should ideally be in
clinical remission at the time of screening colonoscopy so as
to minimize confusion between inﬂammation and dysplasia
on histology.
Dysplasia in the colon of a patient with IBD can be so
called “ﬂat dysplasia” that by white light looks indistinguish-
able from the surrounding tissue. Therefore, the current
standard of care for colon cancer screening in IBD includes
random 4 quadrant biopsies. These are carried out at regular
10cm intervals for at least 33 biopsies to achieve optimal
sensitivity. All biopsies from each area should be placed in
separate, carefully labeled jars. This screening should only
be done in areas known to be involved in the past (i.e., the
right colon does not need to be surveyed in left-sided UC).
A patient that has ﬂat high-grade dysplasia detected in any
one area, or at least two areas of ﬂat low-grade dysplasia
should be advised colectomy. If a patient has one area of
ﬂat low-grade dysplasia detected upon random sampling
(and that is veriﬁed by a second gastrointestinal pathologist),
then a discussion should follow with the patient with
regards to colectomy versus further screening colonoscopies
at a reduced interval. Several studies have documented
an increased risk for development to neoplasia from low-
grade dysplasia, and one study found that 4/17 (23.5%)
of resected colon specimens for ﬂat low-grade dysplasia
harbored advanced neoplasia [36].
What else should the endoscopist look for during a
screening colonoscopy in a patient with IBD? As in a
standard screening colonoscopy, careful attention must be
placed on all masses, polypoid lesions, and other protruding
lesions from the mucosa. As mentioned, strictures need
careful attention particularly in UC where a stricture is
cancer until proven otherwise. Polyps in noninﬂamed areas
are likely sporadic (Figure 4(a)) and should be treated as
in the non-IBD patient. If dysplasia is detected in any
protruding lesion in an area of current or previous inﬂam-
mation, this is referred to as a dysplasia-associated mass
or lesion or “DALM.” Presently, this is further classiﬁed
as an “adenoma-like” DALM or a “non-adenoma-like”
DALM. The former lesion is well circumscribed, sessile, or
pedunculated, without ulceration or bleeding, and resembles
as p o r a d i ca d e n o m a( Figure 4(b)). In contrast, the non-
adenoma-like DALM is not well circumscribed, is broad-
based and irregular, and is often associated with bleeding
or ulceration (Figure 4(c)). On the surveillance colonoscopy,
these lesions should be removed in their entirety or biopsied
if this is not possible. The area around the base should
be biopsied and tattooed. If an adenoma-like DALM is
conﬁdently removed and the base is negative for dysplasia,
then surveillance may be resumed. It has been shown that
adenoma-like lesions arising in the setting of colitis have a
benign course [37, 38]. If the area is not completely removed
and if there is any evidence of dysplasia at the base or if there
is dysplasia detected anywhere else in the colon, then the
patient should be advised colectomy. A non-adenoma-like
DALM with irregular borders or ﬂat, spreading appearance
that is endoscopically unresectable warrants colectomy given
the associated high risk of colon cancer [39].
Inﬂammatory polyps can be seen at endoscopy in
patients with IBD (Figure 4(d)). These are likely benign
lesions caused by the healing of erosive inﬂammation. The
histology of pseudopolyps is characteristic, and they should
therefore be biopsied or removed if encountered. They
appear as polypoid lesions that can be longer in dimension
thantheyarewide.Theirpresencemayinterferewiththesafe
detection of dysplasia and DALMs.
T h e r eh a v eb e e nr e c e n ta d v a n c e si no p t i c a lm e t h o d sa n d
dye systems in order to more accurately detect dysplasia.
Although these techniques have not been incorporated into
recent guidelines, they may allow for targeted biopsies and
eliminate the need for random biopsies. The most promising6 Diagnostic and Therapeutic Endoscopy
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Figure 4: Protruding lesions seen during colon cancer screening in IBD. A patient with left-sided ulcerative colitis was found to have
a sporadic adenomatous polyp (black arrow) at the ileocecal valve (a). An adenoma-like DALM (black arrow) in an area of previous
inﬂammation (b) and a non-adenoma-like DALM (black arrow) (c) were identiﬁed in 2 patients screened for colon cancer. Pseudopolyps
were found in a patient with longstanding ulcerative colitis (d).
technique to date and one that has been endorsed recently
by the Crohn’s and Colitis Foundation of America Colon
CancerinIBDStudyGroup[40]ischromoendoscopy.Inthis
technique, a dye such as methylene blue or indigo carmine
is applied to the colon either randomly or selectively to
highlight areas of dysplasia. Methylene blue is an absorptive
dye that is taken up by normal tissue but not dysplastic
tissue, and indigo carmine is a contrast dye that pools in
areas of abnormal dysplastic tissue. Several recent studies
have shown that chromoendoscopy increases the sensitivity
for the detection of dysplasia. A recently published meta-
analysis calculated a pooled incremental yield of chro-
moendoscopy over white light for dysplasia detection. They
were able to ﬁnd that in the 6 studies of 1277 patients,
chromoendoscopy was signiﬁcantly better than white light
for the detection of dysplasia in colonic IBD [41]. In the
technical review and position statement published by the
AGA, the authors concluded that targeted biopsies using
chromoendoscopy performed by endoscopists experienced
in this technique is a reasonable screening alternative to
the random sampling of colon using standard white light
[31, 32]. In the AGA Institute technology assessment on
image-enhanced endoscopy (IEE), the authors conclude that
IEE may increase the yield of detection of dysplasia and as
such is recommended for patients with long-standing UC
[42]. Other techniques that are currently under study but are
not yet proven for widespread clinical use include confocal
microendoscopy and narrow-band imaging.
5. Endoscopic Interventions in IBD
A clinical consequence of many phenotypes of Crohn’s
disease is stricturing of the intestine. This most commonly
occurs at a surgical anastomosis, in the terminal ileum, at
the ileocecal valve, and in the colon. Because it is essential
to conserve bowel in order to prevent problems such as
short gut syndrome, the idea of dilation of strictures using
endoscopy is attractive. Studies have shown that endoscopic
balloon dilation can be performed safely with minimal
complications and can provide years of symptom and
surgery-free life [43]. One prospective study showed that
the length and location of a stricture may predict the long-
term success of the dilation [44]. Of the 55 patients that
underwent dilation of 74 symptomatic strictures, only 24%
of these patients ultimately required surgery after a median
44 month followup. These strictures were on average 7.5cm
compared with 2.5cm for the patients that did not require
surgery and were all located in the terminal ileum. In the
largest series published to date [45], 237 dilations were
performed on 138 patients and followed for a median 5.8
years (5% complication rate, 97% immediate success rate,
84% were anastomotic strictures, all strictures were <5cm
in length). Because of recurrent symptoms, 46% of these
patients required subsequent dilation, and 24% required
surgery. Interestingly, neither the degree of clinical activity
of inﬂammation at the time of dilation as assessed by CRP
andendoscopicdiseaseactivity,northeconcomitantmedical
therapyfollowingdilationinﬂuencedfutureneedfordilationDiagnostic and Therapeutic Endoscopy 7
or surgery. There are reports as well of endoscopic dilation
using double-balloon enteroscopy for symptomatic small
intestinal strictures that are out of reach of the standard
upper endoscope [46].
6. Conclusions
Presented in this review are the many ways in which
endoscopy is used in the diagnosis and management of
IBD patients. Current research is focusing on the role of
mucosal healing as assessed by endoscopy as an endpoint
for medical therapy and in postoperative surveillance. The
future is promising for cancer and dysplasia surveillance
with newer optical equipment and dyes to allow for targeted
biopsies. Overall, the diagnosis and management of IBD
still starts with a careful history and physical exam. In
the appropriately selected patient, endoscopy can provide
valuable clinical information to supplement or solidify the
clinical impression. The role of endoscopy in IBD is ever
evolving and is an important target of clinical education and
research.
Conﬂict of Interests
The author reports no conﬂict of interests.
Acknowledgments
Thanks are due to Fred Makrauer M.D. for the use of
the image in Figure 4(a) and for all of his academic and
career mentorship. Thanks are due to the Crohn’s and Colitis
Foundation of America for their support of the author’s
research and to their dedication to teaching, research, and
patient care in inﬂammatory bowel disease.
References
[1] J. A. Leighton, B. Shen, T. H. Baron et al., “ASGE guideline:
endoscopy in the diagnosis and treatment of inﬂammatory
bowel disease,” Gastrointestinal Endoscopy,v o l .6 3 ,n o .4 ,p p .
558–565, 2006.
[2] J. D. Waye, “Endoscopy in inﬂammatory bowel disease:
indicationsanddiﬀerentialdiagnosis,”MedicalClinicsofNorth
America, vol. 74, no. 1, pp. 51–65, 1990.
[3] A. Pera, P. Bellando, and D. Caldera, “Colonoscopy in inﬂam-
matory bowel disease. Diagnostic accuracy and proposal of an
endoscopic score,” Gastroenterology, vol. 92, no. 1, pp. 181–
185, 1987.
[4] M. Joo and R. D. Odze, “Rectal sparing and skip lesions in
ulcerative colitis: a comparative study of endoscopic and his-
tologic ﬁndings in patients who underwent proctocolectomy,”
American Journal of Surgical Pathology, vol. 34, no. 5, pp. 689–
696, 2010.
[ 5 ]K .W .S c h r o e d e r ,W .J .T r e m a i n e ,a n dD .M .I l s t r u p ,“ C o a t e d
oral 5-aminosalicylic acid therapy for mildly to moderately
activeulcerativecolitis:arandomizedstudy,”TheNewEngland
Journal of Medicine, vol. 317, no. 26, pp. 1625–1629, 1987.
[ 6 ]F .R .Z w a s ,N .A .B o n h e i m ,C .A .B e r k e n ,a n dS .G r a y ,
“Ileoscopy as an important tool for the diagnosis of Crohn’s
disease: a report of seven cases,” Gastrointestinal Endoscopy,
vol. 40, no. 1, pp. 89–91, 1994.
[7] H. Haskell, C. W. Andrews Jr., S. I. Ready et al., “Pathologic
features and clinical signiﬁcance of ”backwash” ileitis in
ulcerative colitis,” American Journal of Surgical Pathology, vol.
29, no. 11, pp. 1472–1481, 2005.
[8] G. Coremans, P. Rutgeerts, K. Geboes, J. Van den Oord,
E. Ponette, and G. Vantrappen, “The value of ileoscopy
with biopsy in the diagnosis of intestinal Crohn’s disease,”
Gastrointestinal Endoscopy, vol. 30, no. 3, pp. 167–172, 1984.
[9] C. N. Bernstein, F. Shanahan, P. A. Anton, and W. M. Wein-
stein, “Patchiness of mucosal inﬂammation in treated ulcer-
ative colitis: a prospective study,” Gastrointestinal Endoscopy,
vol. 42, no. 3, pp. 232–237, 1995.
[10] J. N. Glickman, A. Bousvaros, F. A. Farraye et al., “Pediatric
patients with untreated ulcerative colitis may present initially
with unusual morphologic ﬁndings,” American Journal of
Surgical Pathology, vol. 28, no. 2, pp. 190–197, 2004.
[11] Y. Nasseri, G. Melmed, H. L. Wang, S. Targan, and P. Fleshner,
“Rigoroushistopathologicalassessmentofthecolectomyspec-
imen in patients with inﬂammatory bowel disease unclassiﬁed
does not predict outcome after ileal pouch-anal anastomosis,”
American Journal of Gastroenterology, vol. 105, no. 1, pp. 155–
161, 2010.
[12] G. D’Haens, K. Geboes, M. Peeters, F. Baert, N. Ectors, and P.
Rutgeerts, “Patchy cecal inﬂammation associated with distal
ulcerative colitis: a prospective endoscopic study,” American
JournalofGastroenterology,vol.92,no.8,pp.1275–1279,1997.
[13] G. J. Mantzaris, A. Hatzis, E. Archavlis et al., “The role
of colonoscopy in the diﬀerential diagnosis of acute, severe
hemorrhagic colitis,” Endoscopy, vol. 27, no. 9, pp. 645–653,
1995.
[14] F. J. Tedesco, R. D. Hardin, R. N. Harper, and B. H. Edwards,
“Infectious colitis endoscopically simulating inﬂammatory
bowel disease: a prospective evaluation,” Gastrointestinal
Endoscopy, vol. 29, no. 3, pp. 195–197, 1983.
[15] D.K.Bhargava,H.D.Tandon,andT.C.Chawla,“Diagnosisof
ileocecal and colonic tuberculosis by colonoscopy,” Gastroin-
testinal Endoscopy, vol. 31, no. 2, pp. 68–70, 1985.
[16] C. M. Surawicz, R. C. Haggitt, M. Husseman, and L. V.
McFarland, “Mucosal biopsy diagnosis of colitis: acute self-
limited colitis and idiopathic inﬂammatory bowel disease,”
Gastroenterology, vol. 107, no. 3, pp. 755–763, 1994.
[17] M. Stolte and F. O. Hartmann, “Misinterpretation of NSAID-
induced Colopathy as Crohn’s disease,” Zeitschrift fur Gas-
troenterologie, vol. 48, no. 4, pp. 472–475, 2010.
[18] M. J. Wagtmans, R. A. van Hogezand, G. Griﬃoen, H. W.
Verspaget, and C. B. Lamers, “Crohn’s disease of the upper
gastrointestinaltract,”NetherlandsJournalofMedicine,vol.50,
no. 2, supplement, pp. S2–S7, 1997.
[19] J. M. Tobin, B. Sinha, P. Ramani, A. R. H. Saleh, and M. S.
Murphy, “Upper gastrointestinal mucosal disease in pediatric
Crohn disease and ulcerative colitis: a blinded, controlled
study,” Journal of Pediatric Gastroenterology and Nutrition, vol.
32, no. 4, pp. 443–448, 2001.
[20] R. Valdez, H. D. Appelman, M. P. Bronner, and J. K. Greenson,
“Diﬀuse duodenitis associated with ulcerative colitis,” Amer-
ican Journal of Surgical Pathology, vol. 24, no. 10, pp. 1407–
1413, 2000.
[21] J. A. Leighton, “The Role of Endoscopic Imaging of the Small
Bowel in Clinical Practice,” American Journal of Gastroenterol-
ogy, 2010.
[22] G. Pineton De Chambrun, L. Peyrin-Biroulet, M. L´ emann,
and J. Colombel, “Clinical implications of mucosal healing for
themanagementofIBD,”NatureReviewsGastroenterologyand
Hepatology, vol. 7, no. 1, pp. 15–29, 2010.8 Diagnostic and Therapeutic Endoscopy
[23] G. R. Lichtenstein and P. Rutgeerts, “Importance of mucosal
healing in ulcerative colitis,” Inﬂammatory Bowel Diseases, vol.
16, no. 2, pp. 338–346, 2010.
[24] P. Rutgeerts, B. G. Feagan, G. R. Lichtenstein et al., “Com-
parison of scheduled and episodic treatment strategies of
inﬂiximab in Crohn’s disease,” Gastroenterology, vol. 126, no.
2, pp. 402–413, 2004.
[25] M. Regueiro, J. Rodemann, K. E. Kip et al., “Physician
assessment of ulcerative colitis activity correlates poorly with
endoscopic disease activity,” Inﬂammatory Bowel Diseases, vol.
17, no. 4, pp. 1008–1014, 2011.
[26] P .R utgeerts,K.Geboes,G.V antrappen,J .Beyls,R.K err emans,
and M. Hiele, “Predictability of the postoperative course of
Crohn’s disease,” Gastroenterology, vol. 99, no. 4, pp. 956–963,
1990.
[27] P.RutgeertsandG.VanAssche,“Whatistheroleofendoscopy
in the postoperative management of Crohn’s disease?” Inﬂam-
matory Bowel Diseases, vol. 14, supplement 2, pp. S179—S180,
2008.
[28] B. Shen, J. P. Achkar, B. A. Lashner et al., “Endoscopic and
histologic evaluation together with symptom assessment are
required to diagnose pouchitis,” Gastroenterology, vol. 121, no.
2, pp. 261–267, 2001.
[ 2 9 ]B .S h e n ,V .W .F a z i o ,F .H .R e m z ie ta l . ,“ C o m p r e h e n s i v e
evaluation of inﬂammatory and noninﬂammatory sequelae of
ileal pouch-anal anastomoses,” American Journal of Gastroen-
terology, vol. 100, no. 1, pp. 93–101, 2005.
[30] S. Ben-Horin, M. Margalit, P. Bossuyt et al., “Prevalence and
clinical impact of endoscopic pseudomembranes in patients
with inﬂammatory bowel disease and Clostridium diﬃcile
infection,” Journal of Crohn’s and Colitis, vol. 4, no. 2, pp. 194–
198, 2010.
[31] F. A. Farraye, R. D. Odze, J. Eaden, and S. H. Itzkowitz,
“AGA medical position statement on the diagnosis and
management of colorectal neoplasia in inﬂammatory bowel
disease,” Gastroenterology, vol. 138, no. 2, pp. 738–745, 2010.
[32] F. A. Farraye, R. D. Odze, J. Eaden, and S. H. Itzkowitz, “AGA
technical review on the diagnosis and management of colorec-
talneoplasiaininﬂammatoryboweldisease,”Gastroenterology,
vol. 138, no. 2, pp. 746–774.e4, 2010.
[33] S. Friedman, P. H. Rubin, C. Bodian, N. Harpaz, and D. H.
Present, “Screening and surveillance colonoscopy in chronic
Crohn’s colitis: results of a surveillance program spanning 25
years,” Clinical Gastroenterology and Hepatology, vol. 6, no. 9,
pp. 993–998, 2008.
[34] J. A. Eaden and J. F. Mayberry, “Guidelines for screening
and surveillance of asymptomatic colorectal cancer in patients
with inﬂammatory bowel disease,” Gut, vol. 51, no. 5, pp. v10–
v12, 2002.
[35] M. Rutter, B. Saunders, K. Wilkinson et al., “Severity of
inﬂammation is a risk factor for colorectal neoplasia in
ulcerative colitis,” Gastroenterology, vol. 126, no. 2, pp. 451–
459, 2004.
[36] T. Ullman, V. Croog, N. Harpaz, D. Sachar, and S. Itzkowitz,
“Progression of Flat Low-Grade Dysplasia to Advanced Neo-
plasia in Patients with Ulcerative Colitis,” Gastroenterology,
vol. 125, no. 5, pp. 1311–1319, 2003.
[37] M. Engelsgjerd, F. A. Farraye, and R. D. Odze, “Polypectomy
maybeadequatetreatmentforadenoma-likedysplasticlesions
in chronic ulcerative colitis,” Gastroenterology, vol. 117, no. 6,
pp. 1288–1294, 1999.
[38] R.D .Odz e,F .A.F arra y e,J .L.H ec ht,andJ .L.H o rnic k,“L o ng-
termfollow-upafterpolypectomytreatmentforadenoma-like
dysplastic lesions in ulcerative colitis,” Clinical Gastroenterol-
ogy and Hepatology, vol. 2, no. 7, pp. 534–541, 2004.
[39] M. O. Blackstone, R. H. Riddell, B. H. Rodgers, and B. Levin,
“Dysplasia-associated lesion or mass (DALM) detected by
colonoscopy in long-standing ulcerative colitis: an indication
for colectomy,” Gastroenterology, vol. 80, no. 2, pp. 366–374,
1981.
[40] S. H. Itzkowitz, D. H. Present, V. Binder et al., “Consensus
conference: colorectal cancer screening and surveillance in
inﬂammatory bowel disease,” Inﬂammatory Bowel Diseases,
vol. 11, no. 3, pp. 314–321, 2005.
[41] V. Subramanian, J. Mannath, K. Ragunath, and C. J. Hawkey,
“Meta-analysis: the diagnostic yield of chromoendoscopy for
detecting dysplasia in patients with colonic inﬂammatory
bowel disease,” Alimentary Pharmacology and Therapeutics,
vol. 33, no. 3, pp. 304–312, 2011.
[42] T. Kaltenbach, Y. Sano, S. Friedland, and R. Soetikno,
“American gastroenterological association (AGA) institute
technology assessment on image-enhanced endoscopy,” Gas-
troenterology, vol. 134, no. 1, pp. 327–340, 2008.
[43] D.Scimeca,F.Mocciaro,M.Cottoneetal.,“Eﬃcacyandsafety
of endoscopic balloon dilation of symptomatic intestinal
Crohn’s disease strictures,” Digestive and Liver Disease, vol. 43,
no. 2, pp. 121–125, 2011.
[44] T. Mueller, B. Rieder, G. Bechtner, and A. Pfeiﬀer, “The
response of Crohn’s strictures to endoscopic balloon dilation,”
Alimentary Pharmacology and Therapeutics,v o l .3 1 ,n o .6 ,p p .
634–639, 2010.
[45] C. Thienpont, A. D’Hoore, S. Vermeire et al., “Long-term
outcome of endoscopic dilatation in patients with Crohn’s
disease is not aﬀected by disease activity or medical therapy,”
Gut, vol. 59, no. 3, pp. 320–324, 2010.
[46] F. Hirai, T. Beppu, S. Sou, T. Seki, K. Yao, and T. Mat-
sui, “Endoscopic balloon dilatation using double-balloon
endoscopy is a useful and safe treatment for small intestinal
strictures in crohn’s disease,” Digestive Endoscopy, vol. 22, no.
3, pp. 200–204, 2010.